尤瑞克林在青年缺血性脑卒中的应用价值

Application Value of Urinary Kallidinogenase in Young Patients with Ischemic Stroke

目的探讨尤瑞克林在青年缺血性脑卒中的临床应用价值。方法将72例急性缺血性脑卒中患者随机分为治疗组和对照组,每组36例。治疗组接受尤瑞克林和依达拉奉治疗,对照组接受相同剂量的依达拉奉及银杏达莫活血化瘀治疗。比较两组患者治疗前及治疗第7、14天时的美国国立卫生研究院脑卒中量表(NIHSS)评分,以及治疗前及治疗第14天时的日常生活能力(ADL)评分。结果两组治疗第7、14天时,NIHSS评分均较治疗前显著降低,且治疗第14天时治疗组NIHSS评分显著低于对照组。两组患者治疗第14天时,ADL较治疗前显著改善,治疗组改善情况显著优于对照组,且治疗组显效率及总有效率显著高于对照组,差异有统计学意义(P<0.01)。结论尤瑞克林能有效改善青年缺血性脑卒中的神经功能损伤,提高ADL及临床有效率。

Objective To explore the clinical application of urinary kallidinogenase in young patients with ischemic stroke. Methods Seventy-two young patients with acute ischemic stroke were randomly divided into treatment group and control group, 36 cases in each group. The patients in treatment group were treated by urinary kallidinogenase and edaravone, while those in control group treated by the same dosage of edaravone and ginkgo- damole to activate blood to remove blood stasis. The United States National Institutes of Health Stroke Scale （NIHSS） score before treatment and on the 7th and 14th day of treatment as well as activity of daily living （ADL） before treatment and on the 14th day of treatment were compared in two groups. Results On the 7th and 14th day of treatment, NIHSS scores in two groups were decreased compared with treatment before, and that on the 14th day in treatment group was significantly lower than in control group. On the 14th day of treatment, ADL in two groups was obviously improved compared with treatment before, and the improved condition, the marked effective rate and total effective rate in treatment group were all evidently higher than in control group, which showed significant differences. Conclusion Urinary kallidinogenase can effectively ameliorate the nerve function injury of young patients with ischemic stroke, improve ADL and clinical efficiency.